1
40
12
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.2165/00003495-200363020-00005" target="_blank" rel="noreferrer noopener">http://doi.org/10.2165/00003495-200363020-00005</a>
Pages
181–205
Issue
2
Volume
63
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
International guidelines for the treatment of community-acquired pneumonia in adults: the role of macrolides.
Publisher
An entity responsible for making the resource available
Drugs
Date
A point or period of time associated with an event in the lifecycle of the resource
2003
2003-01-15
Subject
The topic of the resource
Antibiotics; Outpatients; Risk Assessment; Methicillin Resistance; Inpatients; Clinical Trials; Practice Guidelines; Drug Resistance; Microbial; Nonexperimental Studies; Pneumonia – Drug Therapy; Community-Acquired Infections – Drug Therapy; Pneumonia – Etiology; Macrolide – Therapeutic Use; Streptococcal Infections – Drug Therapy; Community-Acquired Infections – Etiology; Immune System – Drug Effects; Macrolide – Pharmacodynamics
Creator
An entity primarily responsible for making the resource
File T M Jr; Tan J S
Description
An account of the resource
The significance of community-acquired pneumonia (CAP) has led to the publication of guidelines from numerous international organisations. Because the macrolide class of antimicrobials is active against most of the key pathogens associated with CAP, agents from this class are commonly included in recommendations from these guidelines. However, there are differences among the various guidelines concerning the positioning of the macrolides for empirical therapy. An important factor concerning the use of macrolides for CAP is the emergence of resistance of Streptococcus pneumoniae over the past decade. The rate of S. pneumoniae resistance to macrolides ranges from 4 to 70% of strains in worldwide surveillance studies. The most common mechanisms of resistance include methylation of a ribosomal target encoded by the erm gene and efflux of the macrolides by a cell membrane protein transporter, encoded by the mef gene. S. pneumoniae strains with the mef gene are resistant at a lower level (with minimum inhibitory concentration [MIC] values generally 1-16 microg/ml) than erm resistant strains; and it is possible that such strains may be inhibited if sufficiently high levels of macrolide can be obtained at the infected site. Currently mef-associated resistance predominates in North America, whereas erm predominates in Europe. Until recently, reports of failure of treatment of CAP with macrolides has been rare, particularly for patients with low-risk for drug-resistant strains. However, since 2000, several patients treated with an oral macrolide who have subsequently required admission to the hospital for macrolide-resistant S. pneumoniae (MRSP) bacteraemia have been reported in the literature. Major issues, which are fundamental to the use of the macrolides as recommended in the various guidelines, include the importance of providing therapy for 'atypical' pathogens and the clinical significance of MRSP. Presently, the macrolides are more prominently recommended in the North American guidelines than in other parts of the world. The difference in the emphasis placed on the importance of the atypical pathogens as well as the expression of MRSP in North America compared with Europe partly explains this variance.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.2165/00003495-200363020-00005" target="_blank" rel="noreferrer noopener">10.2165/00003495-200363020-00005</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2003
Antibiotics
Clinical Trials
Community-Acquired Infections – Drug Therapy
Community-Acquired Infections – Etiology
Department of Internal Medicine
Drug Resistance
Drugs
File T M Jr
Immune System – Drug Effects
Inpatients
Macrolide – Pharmacodynamics
Macrolide – Therapeutic Use
Methicillin Resistance
Microbial
NEOMED College of Medicine
Nonexperimental Studies
Outpatients
Pneumonia – Drug Therapy
Pneumonia – Etiology
Practice Guidelines
Risk Assessment
Streptococcal Infections – Drug Therapy
Tan J S
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1378/chest.125.5.1888" target="_blank" rel="noreferrer noopener">http://doi.org/10.1378/chest.125.5.1888</a>
Pages
1888–1901
Issue
5
Volume
125
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Guidelines for empiric antimicrobial prescribing in community-acquired pneumonia.
Publisher
An entity responsible for making the resource available
Chest
Date
A point or period of time associated with an event in the lifecycle of the resource
2004
2004-05
Subject
The topic of the resource
Antibiotics; United States; Canada; Europe; Comparative Studies; Practice Guidelines; Drug Resistance; Pneumonia; Microbial; Antiinfective Agents; Community-Acquired Infections – Drug Therapy; Bacterial – Drug Therapy; Antibiotics – Administration and Dosage; Fluoroquinolone – Therapeutic Use; Macrolide – Therapeutic Use; Lactam – Therapeutic Use
Creator
An entity primarily responsible for making the resource
File T M Jr; Garau J; Blasi F; Chidiac C; Klugman K; Lode H; Lonks JR; Mandell L; Ramirez J; Yu V
Description
An account of the resource
Empiric antimicrobial prescribing for community-acquired pneumonia remains a challenge, despite the availability of treatment guidelines. A number of key differences exist between North American and European guidelines, mainly in the outpatient setting. The North American approach is to use initial antimicrobial therapy, which provides coverage for Streptococcus pneumoniae plus atypical pathogens. Europeans tend to focus on providing pneumococcal coverage with less emphasis on covering for an atypical pathogen. Ambulatory patients without comorbidity are more likely to receive macrolide therapy in North America, whereas in Europe these patients would probably receive a beta-lactam agent. Major issues that are fundamental to this difference include the importance of providing therapy for atypical pathogens and the clinical significance of macrolide-resistant S pneumoniae. Prospective data are required to evaluate which of these two approaches offers clinical superiority.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1378/chest.125.5.1888" target="_blank" rel="noreferrer noopener">10.1378/chest.125.5.1888</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2004
Antibiotics
Antibiotics – Administration and Dosage
Antiinfective Agents
Bacterial – Drug Therapy
Blasi F
Canada
Chest
Chidiac C
Community-Acquired Infections – Drug Therapy
Comparative Studies
Department of Internal Medicine
Drug Resistance
Europe
File T M Jr
Fluoroquinolone – Therapeutic Use
Garau J
Klugman K
Lactam – Therapeutic Use
Lode H
Lonks JR
Macrolide – Therapeutic Use
Mandell L
Microbial
NEOMED College of Medicine
Pneumonia
Practice Guidelines
Ramirez J
United States
Yu V
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1016/j.cll.2004.03.003" target="_blank" rel="noreferrer noopener">http://doi.org/10.1016/j.cll.2004.03.003</a>
Pages
531–551
Issue
2
Volume
24
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Evolution of amoxicillin/clavulanate in the treatment of adults with acute bacterial rhinosinusitis and community-acquired pneumonia in response to antimicrobial-resistance patterns.
Publisher
An entity responsible for making the resource available
Clinics in Laboratory Medicine
Date
A point or period of time associated with an event in the lifecycle of the resource
2004
2004-06
Subject
The topic of the resource
Antibiotics; Drug Resistance; Microbial; Microbial Culture and Sensitivity Tests; Pneumonia – Drug Therapy; Community-Acquired Infections – Drug Therapy; Pneumonia – Microbiology; Community-Acquired Infections – Microbiology; Bacteria – Drug Effects; Combined – Therapeutic Use; Rhinosinusitis – Drug Therapy; Rhinosinusitis – Microbiology
Creator
An entity primarily responsible for making the resource
File T M Jr; Benninger MS; Jacobs MR
Description
An account of the resource
Current treatment guidelines for community-acquired respiratory tract infections no longer depend solely on the characteristics of the patient and the clinical syndrome, but on those of the offending pathogen, including presence and level of antimicrobial resistance. The most common respiratory tract pathogens known to cause acute bacterial rhinosinusitis (ABRS) and community-acquired pneumonia (CAP) include Streptococcus pneumoniae and Haemophilus influenzae. The prevalence of antimicrobial resistance, especially b-lactum and macrolide resistance, among S pneumoniae and H influenzae has increased dramatically during the past 2 decades, diminishing the activity of many older antimicrobials against resistant organisms. A pharmacokinetically enhanced formulation of amoxicillin/clavulanate has been developed to fulfill the need for an oral b-lactam antimicrobial that achieves a greater time that the serum drug concentration exceeds the minimum inhibitory concentration (T \textgreater MIC) of antimicrobials against pathogens than conventional formulations to improve activity against S pneumoniae with reduced susceptibility to penicillin. The b-lactamase inhibitor clavulanate allows for coverage of b-lactamase-producing pathogens, such as H influenzae and M catarrhalis. This article reviews the rationale for, and evolution of, oral amoxicillin clavulanate for ABRS and CAP. Copyright © 2004 by Elsevier Science (USA).
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1016/j.cll.2004.03.003" target="_blank" rel="noreferrer noopener">10.1016/j.cll.2004.03.003</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2004
Antibiotics
Bacteria – Drug Effects
Benninger MS
Clinics in laboratory medicine
Combined – Therapeutic Use
Community-Acquired Infections – Drug Therapy
Community-Acquired Infections – Microbiology
Department of Internal Medicine
Drug Resistance
File T M Jr
Jacobs MR
Microbial
Microbial Culture and Sensitivity Tests
NEOMED College of Medicine
Pneumonia – Drug Therapy
Pneumonia – Microbiology
Rhinosinusitis – Drug Therapy
Rhinosinusitis – Microbiology
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1016/s0140-6736(03)15021-0" target="_blank" rel="noreferrer noopener">http://doi.org/10.1016/s0140-6736(03)15021-0</a>
Pages
1991–2001
Issue
9400
Volume
362 North American Edition
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Community-acquired pneumonia.
Publisher
An entity responsible for making the resource available
Lancet
Date
A point or period of time associated with an event in the lifecycle of the resource
2003
2003-12-13
Subject
The topic of the resource
Disease Progression; Community-Acquired Infections; Immunocompetence; Drug Resistance; Pneumonia; Bacterial; Microbial; Severity of Illness; Antibiotics – Therapeutic Use; Community-Acquired Infections – Diagnosis; Community-Acquired Infections – Drug Therapy; Community-Acquired Infections – Microbiology; Bacterial – Drug Therapy; Bacterial – Microbiology; Bacterial – Prevention and Control; Community-Acquired Infections – Prevention and Control; Bacterial – Diagnosis; Streptococcus – Drug Effects; Vaccines – Therapeutic Use
Creator
An entity primarily responsible for making the resource
File T M Jr
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1016/s0140-6736(03)15021-0" target="_blank" rel="noreferrer noopener">10.1016/s0140-6736(03)15021-0</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2003
Antibiotics – Therapeutic Use
Bacterial
Bacterial – Diagnosis
Bacterial – Drug Therapy
Bacterial – Microbiology
Bacterial – Prevention and Control
Community-Acquired Infections
Community-Acquired Infections – Diagnosis
Community-Acquired Infections – Drug Therapy
Community-Acquired Infections – Microbiology
Community-Acquired Infections – Prevention and Control
Department of Internal Medicine
Disease Progression
Drug Resistance
File T M Jr
Immunocompetence
Lancet
Microbial
NEOMED College of Medicine
Pneumonia
Severity of Illness
Streptococcus – Drug Effects
Vaccines – Therapeutic Use
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
Pages
534–541
Issue
8
Volume
20
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Community-acquired pneumonia: recent guidelines for therapy.
Publisher
An entity responsible for making the resource available
Journal of Respiratory Diseases
Date
A point or period of time associated with an event in the lifecycle of the resource
1999
1999-08
Subject
The topic of the resource
Pneumonia – Drug Therapy; Community-Acquired Infections – Drug Therapy; Pneumonia – Microbiology; Community-Acquired Infections – Microbiology
Creator
An entity primarily responsible for making the resource
File T M Jr
Description
An account of the resource
The Infectious Diseases Society of America advocates using pathogen-directed therapy whenever possible to help reduce the emergence of drug resistance. Options for empiric therapy for outpatients include a macrolide, a new fluoroquinolone with enhanced activity against Streptococcus pneumoniae, and doxycycline. A newer fluoroquinolone is an appropriate option when drug-resistant S pneumoniae is a concern. For patients requiring hospitalization in a general ward, the preferred options are a beta-lactam plus a macrolide or a new fluoroquinolone with activity against S pneumoniae.
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
1999
Community-Acquired Infections – Drug Therapy
Community-Acquired Infections – Microbiology
Department of Internal Medicine
File T M Jr
Journal of Respiratory Diseases
NEOMED College of Medicine
Pneumonia – Drug Therapy
Pneumonia – Microbiology
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1185/030079904x2556" target="_blank" rel="noreferrer noopener">http://doi.org/10.1185/030079904x2556</a>
Pages
1473–1481
Issue
9
Volume
20
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Clinical implications of 750 mg, 5-day levofloxacin for the treatment of community-acquired pneumonia.
Publisher
An entity responsible for making the resource available
Current Medical Research & Opinion
Date
A point or period of time associated with an event in the lifecycle of the resource
2004
2004-09
Subject
The topic of the resource
Adult; Female; Male; Human; Chi Square Test; Funding Source; Retrospective Design; T-Tests; Kaplan-Meier Estimator; Random Assignment; McNemar's Test; Double-Blind Studies; Log-Rank Test; Pneumonia – Drug Therapy; Community-Acquired Infections – Drug Therapy; Ofloxacin – Administration and Dosage
Creator
An entity primarily responsible for making the resource
File T M Jr; Milkovich G; Tennenberg AM; Xiang JX; Khashab MM; Zadeikis N
Description
An account of the resource
OBJECTIVE: To evaluate the time to symptom resolution and i.v.-to-p.o. transition in community-acquired pneumonia (CAP) patients treated with 750 mg or 500 mg levofloxacin. RESEARCH DESIGN: A retrospective, subset analysis of a multicenter, randomized, double-blind, controlled trial comparing 750 mg levofloxacin for 5 days to 500 mg levofloxacin for 10 days for the treatment of CAP. PATIENTS AND METHODS: A total of 528 CAP patients were included. Baseline symptoms were re-evaluated on Day 3 of therapy, and time to i.v.-to-p.o. transition was recorded for inpatients. RESULTS: For the overall population, 67.4% of patients receiving 750 mg levofloxacin had resolution of fever by Day 3 of therapy, compared to 54.6% of 500 mg treated patients (P = 0.006). Patients who started on 750 mg levofloxacin i.v. (N = 108) transitioned to p.o. in an average of 2.68 days while those starting on 500 mg i.v. (N = 124) transitioned in 2.95 days (P = 0.144). The median time for i.v.-to-p.o. switch was 2.35 days and 2.75 days for patients receiving 750 mg and 500 mg levofloxacin, respectively (P = 0.098, log rank test). By Day 3 of therapy, 68% of patients receiving the 750 mg dose had transitioned from i.v. to p.o. levofloxacin, compared with 61% of the 500 mg group (P = 0.280). The safety profiles were comparable for the two regimens. CONCLUSIONS: The 750 mg levofloxacin dose resulted in a greater proportion of patients with resolution of CAP symptoms by Day 3 when compared with 500 mg therapy. Consequently, the 750 mg regimen trended toward more rapid transition to p.o., potentially resulting in lower overall drug costs. Time to switch from i.v. to p.o. was determined by the investigators' discretion rather than a set protocol. Additionally, length of stay data was not collected in this study, which can significantly impact overall healthcare costs. Further research is required to fully understand the economic impact of the 750 mg, 5-day levofloxacin regimen.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1185/030079904x2556" target="_blank" rel="noreferrer noopener">10.1185/030079904x2556</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2004
Adult
Chi Square Test
Community-Acquired Infections – Drug Therapy
Current Medical Research & Opinion
Department of Internal Medicine
Double-Blind Studies
Female
File T M Jr
Funding Source
Human
Kaplan-Meier Estimator
Khashab MM
Log-Rank Test
Male
McNemar's Test
Milkovich G
NEOMED College of Medicine
Ofloxacin – Administration and Dosage
Pneumonia – Drug Therapy
Random Assignment
Retrospective Design
T-Tests
Tennenberg AM
Xiang JX
Zadeikis N
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.18553/jmcp.2009.15.s2.5" target="_blank" rel="noreferrer noopener">http://doi.org/10.18553/jmcp.2009.15.s2.5</a>
Pages
S5–11
Issue
2
Volume
15
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
The Science of Selecting Antimicrobials for Community-Acquired Pneumonia (CAP)
Publisher
An entity responsible for making the resource available
Journal of Managed Care Pharmacy
Date
A point or period of time associated with an event in the lifecycle of the resource
2009
2009-03-02
Subject
The topic of the resource
Antibiotics; Human; Practice Guidelines; Drug Resistance; Pneumonia; Drug Therapy; Microbial; Combination; Microbial Culture and Sensitivity Tests; Antiinfective Agents; Streptococcus; Gram-Negative Bacteria; Antibiotics – Therapeutic Use; Community-Acquired Infections – Drug Therapy; Bacterial – Drug Therapy; Macrolide – Therapeutic Use; Quinolone – Therapeutic Use; Lactam – Therapeutic Use; Legionnaires' Disease – Drug Therapy
Creator
An entity primarily responsible for making the resource
File T M
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.18553/jmcp.2009.15.s2.5" target="_blank" rel="noreferrer noopener">10.18553/jmcp.2009.15.s2.5</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2009
Antibiotics
Antibiotics – Therapeutic Use
Antiinfective Agents
Bacterial – Drug Therapy
Combination
Community-Acquired Infections – Drug Therapy
Department of Internal Medicine
Drug Resistance
Drug Therapy
File T M
Gram-Negative Bacteria
Human
Journal of Managed Care Pharmacy
Lactam – Therapeutic Use
Legionnaires' Disease – Drug Therapy
Macrolide – Therapeutic Use
Microbial
Microbial Culture and Sensitivity Tests
NEOMED College of Medicine
Pneumonia
Practice Guidelines
Quinolone – Therapeutic Use
Streptococcus
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
Pages
97–99
Issue
9
Volume
32
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Uncomplicated Pure Cellulitis: No Need to Cover for MRSA?
Publisher
An entity responsible for making the resource available
Infectious Disease Alert
Date
A point or period of time associated with an event in the lifecycle of the resource
2013
2013-06
Subject
The topic of the resource
Treatment Outcomes; Cellulitis; Methicillin-Resistant Staphylococcus Aureus; Antibiotics – Therapeutic Use; Community-Acquired Infections – Drug Therapy; Staphylococcal Infections – Drug Therapy; Cellulitis – Drug Therapy; Cellulitis – Diagnosis; Cellulitis – Microbiology; Streptococcal Infections – Drug Therapy
Creator
An entity primarily responsible for making the resource
Watkins Richard R
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2013
Antibiotics – Therapeutic Use
Cellulitis
Cellulitis – Diagnosis
Cellulitis – Drug Therapy
Cellulitis – Microbiology
Community-Acquired Infections – Drug Therapy
Department of Internal Medicine
Infectious Disease Alert
Methicillin-Resistant Staphylococcus aureus
NEOMED College of Medicine
Staphylococcal Infections – Drug Therapy
Streptococcal Infections – Drug Therapy
Treatment Outcomes
Watkins Richard R
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
Pages
1–2
Issue
3
Volume
37
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Statin Use Is Associated With a Lower Risk of Community-acquired Staphylococcus aureus Bacteremia.
Publisher
An entity responsible for making the resource available
Infectious Disease Alert
Date
A point or period of time associated with an event in the lifecycle of the resource
2017
2017-12
Subject
The topic of the resource
Risk Assessment; Drug Resistance; Microbial; Neutrophils; Community-Acquired Infections – Drug Therapy; Cell Physiology – Drug Effects; Staphylococcus Aureus – Drug Effects; Bacteremia – Risk Factors; Biofilms – Drug Effects; Simvastatin – Administration and Dosage; Statins – Economics; Statins – Therapeutic Use
Creator
An entity primarily responsible for making the resource
Watkins Richard R
Description
An account of the resource
A population-based case-control study from Denmark found the use of statins was associated with a decreased risk for community-associated Staphylococcus aureus bacteremia, with the greatest benefit from higher doses.
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2017
Bacteremia – Risk Factors
Biofilms – Drug Effects
Cell Physiology – Drug Effects
Community-Acquired Infections – Drug Therapy
Department of Internal Medicine
Drug Resistance
Infectious Disease Alert
Microbial
NEOMED College of Medicine
Neutrophils
Risk Assessment
Simvastatin – Administration and Dosage
Staphylococcus Aureus – Drug Effects
Statins – Economics
Statins – Therapeutic Use
Watkins Richard R
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1093/jac/dkr096" target="_blank" rel="noreferrer noopener">http://doi.org/10.1093/jac/dkr096</a>
Pages
iii19–32
Volume
66 Suppl 3
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.
Publisher
An entity responsible for making the resource available
The Journal of antimicrobial chemotherapy
Date
A point or period of time associated with an event in the lifecycle of the resource
2011
2011-04
Subject
The topic of the resource
80 and over; 80 and Over; Aged; Bacteria; Bacteria/isolation & purification; Bacterial – Drug Therapy; Bacterial/*drug therapy; Ceftriaxone – Administration and Dosage; Ceftriaxone – Adverse Effects; Ceftriaxone/administration & dosage/adverse effects; Cephalosporins – Administration and Dosage; Cephalosporins – Adverse Effects; Cephalosporins/*administration & dosage/*adverse effects; Community-Acquired Infections – Drug Therapy; Community-Acquired Infections/*drug therapy; Double-Blind Method; Double-Blind Studies; Female; Human; Humans; Infusions; Intravenous; Male; Middle Age; Middle Aged; Pneumonia; Randomized Controlled Trials; Treatment Outcome; Treatment Outcomes
Creator
An entity primarily responsible for making the resource
File Thomas M Jr; Low Donald E; Eckburg Paul B; Talbot George H; Friedland H David; Lee Jon; Llorens Lily; Critchley Ian A; Thye Dirk A
Description
An account of the resource
OBJECTIVES: Ceftaroline, the active form of the prodrug ceftaroline fosamil, is a novel cephalosporin with bactericidal activity against important pathogens associated with community-acquired pneumonia (CAP), including Streptococcus pneumoniae and common Gram-negative pathogens. FOCUS 1 is a randomized, double-blinded, Phase III study that was conducted to evaluate the efficacy and safety of ceftaroline fosamil in treating patients with CAP. The primary objective was to determine non-inferiority [lower limit of 95% confidence interval (CI) \textgreater/= -10%] in clinical cure rates achieved with ceftaroline fosamil compared with those achieved with ceftriaxone in the clinically evaluable (CE) and modified intent-to-treat efficacy (MITTE) populations. METHODS: Patients hospitalized in a non-intensive care unit setting with CAP of Pneumonia Outcomes Research Team (PORT) risk class III or IV requiring intravenous (iv) therapy were randomized (1:1) to receive 600 mg of ceftaroline fosamil iv every 12 h or 1 g of ceftriaxone iv every 24 h. Patients also received two 500 mg doses of oral clarithromycin every 12 h administered on day 1. Clinical cure, microbiological response, adverse events (AEs) and laboratory tests were assessed. FOCUS 1 registration number NCT00621504 (http://clinicaltrials.gov/ct2/show/NCT00621504). RESULTS: Of 613 enrolled patients, 298 received ceftaroline fosamil and 308 received ceftriaxone. Baseline characteristics between treatment groups were comparable. Clinical cure rates were as follows: CE population, 86.6% (194/224) for ceftaroline fosamil and 78.2% (183/234) for ceftriaxone [difference (95% CI), 8.4% (1.4, 15.4)]; and MITTE population, 83.8% (244/291) for ceftaroline fosamil and 77.7% (233/300) for ceftriaxone [difference (95% CI), 6.2% (-0.2, 12.6)]. Clinical cure rates for CAP caused by S. pneumoniae in the microbiological MITTE population were 88.9% (24/27) and 66.7% (20/30) for ceftaroline fosamil and ceftriaxone, respectively. Both agents were well tolerated, with similar rates of AEs, serious AEs, deaths and discontinuations because of an AE. The most common AEs for ceftaroline fosamil-treated patients were diarrhoea, headache, insomnia and nausea, and the most common AEs for ceftriaxone-treated patients were hypokalaemia, hypertension, nausea and diarrhoea. CONCLUSIONS: Ceftaroline fosamil demonstrated high clinical cure and microbiological response rates in hospitalized patients with CAP of PORT risk class III or IV. Ceftaroline fosamil was well tolerated, with a safety profile similar to that of ceftriaxone and consistent with the cephalosporin class. In this study, ceftaroline fosamil was an effective and well-tolerated treatment option for CAP.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1093/jac/dkr096" target="_blank" rel="noreferrer noopener">10.1093/jac/dkr096</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2011
80 and over
Aged
Bacteria
Bacteria/isolation & purification
Bacterial – Drug Therapy
Bacterial/*drug therapy
Ceftriaxone – Administration and Dosage
Ceftriaxone – Adverse Effects
Ceftriaxone/administration & dosage/adverse effects
Cephalosporins – Administration and Dosage
Cephalosporins – Adverse Effects
Cephalosporins/*administration & dosage/*adverse effects
Community-Acquired Infections – Drug Therapy
Community-Acquired Infections/*drug therapy
Critchley Ian A
Department of Internal Medicine
Double-Blind Method
Double-Blind Studies
Eckburg Paul B
Female
File Thomas M Jr
Friedland H David
Human
Humans
Infusions
Intravenous
Lee Jon
Llorens Lily
Low Donald E
Male
Middle Age
Middle Aged
NEOMED College of Medicine
Pneumonia
RANDOMIZED controlled trials
Talbot George H
The Journal of antimicrobial chemotherapy
Thye Dirk A
Treatment Outcome
Treatment Outcomes
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1016/j.idc.2012.11.005" target="_blank" rel="noreferrer noopener">http://doi.org/10.1016/j.idc.2012.11.005</a>
Pages
99–114
Issue
1
Volume
27
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Does empiric therapy for atypical pathogens improve outcomes for patients with CAP?
Publisher
An entity responsible for making the resource available
Infectious disease clinics of North America
Date
A point or period of time associated with an event in the lifecycle of the resource
2013
2013-03
Subject
The topic of the resource
Anti-Bacterial Agents/*therapeutic use; Antibiotic Prophylaxis; Antibiotics – Therapeutic Use; Clinical Trials; Clinical Trials as Topic; Community-Acquired Infections – Drug Therapy; Community-Acquired Infections – Microbiology; Community-Acquired Infections/drug therapy/microbiology; Humans; Pneumonia – Drug Therapy; Pneumonia – Microbiology; Pneumonia/*drug therapy/microbiology
Creator
An entity primarily responsible for making the resource
File Thomas M Jr; Marrie Thomas J
Description
An account of the resource
The present controversy regarding the need to cover atypical pathogens in the empiric therapy of community-acquired pneumonia is related to several issues, including the relevance of terminology, imprecise diagnostic methods, and perceived contradictory results of published evidence. Studies evaluating the time to clinical recovery and the use of earlier endpoints for evaluation suggest that appropriate therapy provides a benefit if an atypical pathogen is a pathogen. Because recent surveillance studies suggest these pathogens are common and until there is the availability of accurate, cost-effective, and easily interpreted laboratory tests to provide the etiologic diagnosis at the time of point of care, empiric therapy of atypical pathogens is supported.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1016/j.idc.2012.11.005" target="_blank" rel="noreferrer noopener">10.1016/j.idc.2012.11.005</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2013
Anti-Bacterial Agents/*therapeutic use
Antibiotic Prophylaxis
Antibiotics – Therapeutic Use
Clinical Trials
Clinical Trials as Topic
Community-Acquired Infections – Drug Therapy
Community-Acquired Infections – Microbiology
Community-Acquired Infections/drug therapy/microbiology
Department of Internal Medicine
File Thomas M Jr
Humans
Infectious disease clinics of North America
Marrie Thomas J
NEOMED College of Medicine
Pneumonia – Drug Therapy
Pneumonia – Microbiology
Pneumonia/*drug therapy/microbiology
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1016/j.amjmed.2010.02.002" target="_blank" rel="noreferrer noopener">http://doi.org/10.1016/j.amjmed.2010.02.002</a>
Pages
S4–15
Issue
4
Volume
123
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Case studies of lower respiratory tract infections: community-acquired pneumonia.
Publisher
An entity responsible for making the resource available
The American journal of medicine
Date
A point or period of time associated with an event in the lifecycle of the resource
2010
2010-04
Subject
The topic of the resource
Acute – Microbiology; Adult; Adult/microbiology; Aged; Anti-Bacterial Agents/*therapeutic use; Antibiotics – Therapeutic Use; Antitubercular Agents – Therapeutic Use; Antitubercular Agents/therapeutic use; Community-Acquired Infections – Diagnosis; Community-Acquired Infections – Drug Therapy; Community-Acquired Infections/diagnosis/drug therapy; Cough; Cough – Microbiology; Cough/microbiology/virology; Diagnosis; Differential; Dyspnea; Fatal Outcome; Female; Fever – Microbiology; Fever/microbiology; Hemoptysis – Microbiology; Hemoptysis/microbiology; Human; Human – Complications; Human – Diagnosis; Human/complications/*diagnosis; Humans; Hypotension – Microbiology; Hypotension/microbiology; Influenza; Leukopenia – Microbiology; Leukopenia/microbiology; Male; Methicillin-Resistant Staphylococcus Aureus; Methicillin-Resistant Staphylococcus aureus/*isolation & purification; Miliary/diagnosis/drug therapy; Multiple Organ Dysfunction Syndrome – Microbiology; Multiple Organ Failure/microbiology; Mycobacterium Tuberculosis; Mycobacterium tuberculosis/isolation & purification; Pneumonia – Diagnosis; Pneumonia – Drug Therapy; Pneumonia – Microbiology; Pneumonia – Therapy; Pneumonia/*diagnosis/*drug therapy/microbiology/therapy; Practice Guidelines; Practice Guidelines as Topic; Respiratory Distress Syndrome; Risk Factors; Severity of Illness Index; Severity of Illness Indices; Smoking; Smoking/adverse effects; Staphylococcal Infections – Diagnosis; Staphylococcal Infections – Drug Therapy; Staphylococcal Infections – Microbiology; Staphylococcal Infections – Therapy; Staphylococcal Infections/*diagnosis/*drug therapy/microbiology/therapy; Tuberculosis; Tuberculosis – Diagnosis; Tuberculosis – Drug Therapy
Creator
An entity primarily responsible for making the resource
File Thomas M Jr
Description
An account of the resource
Community-acquired pneumonia (CAP) is a common and potentially serious illness with significant human and economic costs to society. The recent collaborative statement from the Infectious Diseases Society of America (IDSA) and the American Thoracic Society (ATS) represents the most up-to-date evidence-based guidelines from North America, incorporating important advances in the management of patients with CAP. The cases presented in this review highlight many of the recent recommendations from the IDSA/ATS guidelines.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1016/j.amjmed.2010.02.002" target="_blank" rel="noreferrer noopener">10.1016/j.amjmed.2010.02.002</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2010
Acute – Microbiology
Adult
Adult/microbiology
Aged
Anti-Bacterial Agents/*therapeutic use
Antibiotics – Therapeutic Use
Antitubercular Agents – Therapeutic Use
Antitubercular Agents/therapeutic use
Community-Acquired Infections – Diagnosis
Community-Acquired Infections – Drug Therapy
Community-Acquired Infections/diagnosis/drug therapy
Cough
Cough – Microbiology
Cough/microbiology/virology
Department of Internal Medicine
Diagnosis
Differential
Dyspnea
Fatal Outcome
Female
Fever – Microbiology
Fever/microbiology
File Thomas M Jr
Hemoptysis – Microbiology
Hemoptysis/microbiology
Human
Human – Complications
Human – Diagnosis
Human/complications/*diagnosis
Humans
Hypotension – Microbiology
Hypotension/microbiology
Influenza
Leukopenia – Microbiology
Leukopenia/microbiology
Male
Methicillin-Resistant Staphylococcus aureus
Methicillin-Resistant Staphylococcus aureus/*isolation & purification
Miliary/diagnosis/drug therapy
Multiple Organ Dysfunction Syndrome – Microbiology
Multiple Organ Failure/microbiology
Mycobacterium Tuberculosis
Mycobacterium tuberculosis/isolation & purification
NEOMED College of Medicine
Pneumonia – Diagnosis
Pneumonia – Drug Therapy
Pneumonia – Microbiology
Pneumonia – Therapy
Pneumonia/*diagnosis/*drug therapy/microbiology/therapy
Practice Guidelines
Practice Guidelines as Topic
Respiratory Distress Syndrome
Risk Factors
Severity of Illness Index
Severity of Illness Indices
Smoking
Smoking/adverse effects
Staphylococcal Infections – Diagnosis
Staphylococcal Infections – Drug Therapy
Staphylococcal Infections – Microbiology
Staphylococcal Infections – Therapy
Staphylococcal Infections/*diagnosis/*drug therapy/microbiology/therapy
The American journal of medicine
Tuberculosis
Tuberculosis – Diagnosis
Tuberculosis – Drug Therapy